LIXTClinical Trials•globenewswire•
24/7 Market News: LIXTE Biotechnology Spotlight- Revisiting the “Too Much of a Good Thing” Strategy for LB-100
Sentiment:Neutral (60)
Summary
LIXTE’s (Nasdaq: LIXT) lead compound, LB 100, was featured in Nature Reviews Cancer editorial titled “Too Much of a Good Thing”
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 19, 2025 by globenewswire